



EffeMarket



Non Alcoholic Steatohepatitis (NASH), 2024

September, 2018

Table of Contents

Executive Summary

NASH: Overview

- Signs and Symptoms
- Histologic and risk factors for NAFLD
- Progression of NASH
- NASH Grading and Staging
- Etiology
- Insulin Resistance
- Nash Etiology
- Pathophysiology
- Internal Liver Signals
- Complications

Diagnosis

- Scoring Systems for NASH
- Scheuer and Modified Laennec Scoring System
- Modified Laennec Scoring System

Diagnostic Guidelines

- AALD; ASG; AGA: NASH Diagnostic Recommendation
- EASL, EASD, EASO: NASH Diagnostic Recommendation

Treatment

- PPAR Agonists (Peroxisome proliferator-activator receptors)
- FXR Bile Acid Axis
- Lipid Altering Agents
- Incretin-based Therapies
- Agents targeting inflammation, cell injury or death (apoptosis) and oxidative stress
- Gut and Microbiome related therapies
- Antifibrotic Therapies

Treatment Guidelines

- EASL, EASD, EASO: NASH Treatment Recommendation
- Japanese Society of Gastroenterology: Treatment Guidelines
- Practical Guidelines by Japanese Society of Gastroenterology

Epidemiology

United States

- Prevalent Cases of NASH
- Sub-type Specific Prevalent Cases of NASH
- Diagnosed Cases of NASH

Germany

- Prevalent Cases of NASH
- Sub-type Specific Prevalent Cases of NASH
- Diagnosed Cases of NASH

France

- Prevalent Cases of NASH
- Sub-type Specific Prevalent Cases of NASH
- Diagnosed Cases of NASH

United Kingdom

- Prevalent Cases of NASH
- Sub-type Specific Prevalent Cases of NASH
- Diagnosed Cases of NASH

Spain

- Prevalent Cases of NASH
- Sub-type Specific Prevalent Cases of NASH
- Diagnosed Cases of NASH

Italy

- Prevalent Cases of NASH
- Sub-type Specific Prevalent Cases of NASH
- Diagnosed Cases of NASH

Japan

- Prevalent Cases of NASH
- Sub-type Specific Prevalent Cases of NASH
- Diagnosed Cases of NASH

Market Size of NASH

United States

- Market Size of NASH
- Therapy wise market Size of NASH

EU5

Germany

France

United Kingdom

Spain

Italy

Japan

Pipeline Product Analysis

- Elafibranor

- Cenicriviroc

- Selonsertib

- Obeticholic Acid

Growth Drivers

- Rising Prevalent Cases

- Rising Incident of Obese and Diabetic Population

- Increased Healthcare Costs

- Increasing GDP per capita

- Unmet Needs

Trends

- Increased Research and Development

- Development of NASH Diagnosis Methods and Biomarker

Challenges

- Understanding Disease Pathogenesis

- Diagnostic Challenges

Company Profiles

Gilead

- Business Overview

- Financial Overview

- Product Overview

Intercept

- Business Overview

- Financial Overview

- Product Overview

Allergan

- Business Overview

- Financial Overview

- Product Overview

Galmed Pharmaceuticals

- Business Overview

- Financial Overview

- Product Overview

Genfit

- Business Overview

- Financial Overview

- Product Overview

About EffeMarket

Disclaimer

Contact US

List of Figures

- Figure 1: NAFLD Spectrum
- Figure 2: NASH Etiology via insulin resistance mechanism
- Figure 3: Pathophysiology of NASH
- Figure 4: Complications of NASH
- Figure 5: Diagnostic Algorithm for NASH
- Figure 6: EASL, EASD and EASO Diagnostic Algorithm and Follow up for NASH
- Figure 7: Prevalent Cases of NASH in the United States (2016-2024)
- Figure 8: Sub-type Specific Prevalent Cases of NASH in the United States (2016-2024)
- Figure 9: Diagnosed Cases of NASH in the United States (2016-2024)
- Figure 10: Prevalent Cases of NASH in Germany (2016-2024)
- Figure 11: Sub-type Specific Prevalent Cases of NASH in Germany (2016-2024)
- Figure 12: Diagnosed Cases of NASH in Germany (2016-2024)
- Figure 13: Prevalent Cases of NASH in France (2016-2024)
- Figure 14: Sub-type Specific Prevalent Cases of NASH in France (2016-2024)
- Figure 15: Diagnosed Cases of NASH in France (2016-2024)
- Figure 16: Prevalent Cases of NASH in the United Kingdom (2016-2024)
- Figure 17: Sub-type Specific Prevalent Cases of NASH in the United Kingdom (2016-2024)
- Figure 18: Diagnosed Cases of NASH in the United Kingdom (2016-2024)
- Figure 19: Prevalent Cases of NASH in Spain (2016-2024)
- Figure 20: Sub-type Specific Prevalent Cases of NASH in Spain (2016-2024)
- Figure 21: Diagnosed Cases of NASH in Spain (2016-2024)
- Figure 22: Prevalent Cases of NASH in Italy (2016-2024)
- Figure 23: Sub-type Specific Prevalent Cases of NASH in Italy (2016-2024)
- Figure 24: Diagnosed Cases of NASH in Italy (2016-2024)
- Figure 25: Prevalent Cases of NASH in Japan (2016-2024)
- Figure 26: Sub-type Specific Prevalent Cases of NASH in Japan (2016-2024)
- Figure 27: Diagnosed Cases of NASH in Japan (2016-2024)
- Figure 28: 7 Major Market Size of NASH, In USD Million (2016-2024)
- Figure 29: Market Size of NASH in the United States, in USD Million (2016-2024)
- Figure 30: Therapy Wise Market Size of NASH in the United States, in USD Million (2016-2024)
- Figure 31: EU5 Market Size of NASH, in USD Million (2016-2024)
- Figure 32: Market Size of NASH in Germany, in USD Million (2016-2024)
- Figure 33: Therapy Wise Market Size of NASH in Germany, in USD Million (2016-2024)
- Figure 34: Market Size of NASH in France, in USD Million (2016-2024)
- Figure 35: Therapy Wise Market Size of NASH in France, in USD Million (2016-2024)
- Figure 36: Market Size of NASH in the United Kingdom, in USD Million (2016-2024)
- Figure 37: Therapy Wise Market Size of NASH in United Kingdom, in USD Million (2016-2024)
- Figure 38: Market Size of NASH in Spain, in USD Million (2016-2024)
- Figure 39: Therapy Wise Market Size of NASH in Spain, in USD Million (2016-2024)
- Figure 40: Market Size of NASH in Italy, in USD Million (2016-2024)

Figure 41: Therapy Wise Market Size of NASH in Italy, in USD Million (2016-2024)

Figure 42: Market Size of NASH in Japan, in USD Million (2016-2024)

Figure 43: Therapy Wise Market Size of NASH in Japan, in USD Million (2016-2024)

Figure 44: Gilead Total Revenues in USD Billion (2014-2017)

Figure 45: Gilead Research and Development Expenses in USD Billion (2015-2017)

Figure 46: Intercept Revenue in USD Billion (2013-2017)

Figure 47: Intercept Research and Development Expenses in USD Billion (2013-2017)

Figure 48: Allergan Revenue in USD Billion (2013-2017)

Figure 49: Galmed Research and Development Expenses (2015-2017)

List of Tables

Table 1: NASH Scoring System

Table 2: Modified Laennec Scoring System

Table 3: AALD; ASG;AGA:NASH Diagnostic Recommendation

Table 4: EASL, EASD,EASO: NASH Diagnostic Recommendation

Table 5: Evidence Grade System Used by EASL-EASD-EASO Clinical Practice Guidelines on NAFLD

Table 6: Treatment Guidelines by EASO

Table 7: Practical Guidelines by Japanese Society of Gastroenterology

Table 8: Practical Guidelines by Japanese Society of Gastroenterology

Table 9: Prevalent Cases of NASH in the United States (2016-2024)

Table 10: Sub-type Specific Prevalent Cases of NASH in the United States (2016-2024)

Table 11: Diagnosed Cases of NASH in the United States (2016-2024)

Table 12: Prevalent Cases of NASH in Germany (2016-2024)

Table 13: Sub-type Specific Prevalent Cases of NASH in the Germany (2016-2024)

Table 14: Diagnosed Cases of NASH in Germany (2016-2024)

Table 15: Prevalent Cases of NASH in France (2016-2024)

Table 16: Sub-type Specific Prevalent Cases of NASH in France (2016-2024)

Table 17: Diagnosed Cases of NASH in the France (2016-2024)

Table 18: Prevalent Cases of NASH in the United Kingdom (2016-2024)

Table 19: Sub-type Specific Prevalent Cases of NASH in United Kingdom (2016-2024)

Table 20: Diagnosed Cases of NASH in the UK (2016-2024)

Table 21: Diagnosed Cases of NASH in the Spain (2016-2024)

Table 22: Sub-type specific Cases of NASH in the Spain (2016-2024)

Table 23: Diagnosed Cases of NASH in the Spain (2016-2024)

Table 24: Prevalent Cases of NASH in the Italy (2016-2024)

Table 25: Sub-type Specific Prevalent Cases of NASH in the Italy (2016-2024)

Table 26: Diagnosed Cases of NASH in the Italy (2016-2024)

Table 27: Prevalent Cases of NASH in the Japan (2016-2024) Italy (2016-2024)

Table 28: Sub-type Specific Prevalent Cases of NASH in the Japan (2016-2024)

Table 29: Diagnosed Cases of NASH in the Japan (2016-2024)

Table 30: Major Market Size of NASH , in USD Million (2016-2024)

Table 31: Market Size of NASH in the United States, in USD Million (2016-2024)

Table 32: Therapy Wise Market Size of NASH in the United States, in USD Million (2016-2024)

Table 33: Therapy Wise Market Size of NASH in Germany, in USD Million (2016-2024)

Table 34: Therapy Wise Market Size of NASH in Germany, in USD Million (2016-2024)

Table 35: Therapy Wise Market Size of NASH in France, in USD Million (2016-2024)

Table 36: Therapy Wise Market Size of NASH in France, in USD Million (2016-2024)

Table 37: Therapy Wise Market Size of NASH in the United Kingdom, in USD Million (2016-2024)

Table 38: Therapy Wise Market Size of NASH in the United Kingdom , in USD Million (2016-2024)

Table 39: Market Size of NASH in the Spain, in USD Million (2016-2024)

Table 40: Therapy Wise Market Size of NASH in the Spain , in USD Million (2016-2024)

Table 41: Market Size of NASH in the Italy , in USD Million (2016-2024)

Table 42: Therapy Wise Market Size of NASH in the Italy , in USD Million (2016-2024)

Table 43: Market Size of NASH in the Japan, in USD Million (2016-2024)

Table 44: Therapy Wise Market Size of NASH in the Japan , in USD Million (2016-2024)

Table 45: Phase III Drug Analysis for NASH

Table 46: Elafibranor Clinical Trial Description

Table 47: Cenicriviroc Clinical Trial Description

Table 48: Cenicriviroc Clinical Trial Description

Table 49: Obeticholic acid Clinical Trial Description

Table 50: Endpoints in Clinical Trials

Table 51: Gilead Product Overview

Executive Summary

Non Alcoholic Steatohepatitis or NASH is one of the emerging common liver disease and is often referred to as a silent liver disease. The main feature that characterizes NASH from the entire spectrum of NAFLD is the accumulation of fat leading to major progression of disease towards cirrhosis which is generally diagnosed at the later stages. The global NASH market is expected to show an extensively significant growth in the near future owing to rising prevalence of obesity, lifestyle changes, cardiovascular diseases etc. As per American Association for the Study of Liver Disease (AASLD) the annual clinical burden of NAFLD is projected to be substantial in both the United States and the Europe-4. In the United States, over 12 million incident cases of NAFL and over 600,000 incident cases of NASH are predicted, with proportionally similar results in Europe. The Global NASH market is expected to increase from 1300 USD million in 2016 to 24036 USD million in 2024 with the CAGR of 44 percent for the forecasted period of 2016-2024 in seven major markets like US, EU5 and Japan. United States accounts for the largest share of the market which accounts for approximately 46.1 percent followed by EU5 countries (42.4 Percent) and Japan (45.1 percent) in 2016 owing to highest prevalent cases, increasing research activities and improved healthcare resources. As for the NASH, there is no approved marketed drug yet. Most of the supportive therapies available therapies are contributing for the largest share of market. Emerging drugs such as Ocaliva, Elafibranor, Cenicriviroc, Selonsertib are expected to get launched in 2023, 2022,2020 respectively shall fuel the market growth. Apart from rising incidence of prevalent cases, obese population other factors like increased healthcare costs, increased GDP per capita are some of the growth drivers that will fuel the market in near future, though NASH market is obvious to encounter some of the major challenges like diagnostic challenges, complicated disease etiology and less awareness among the masses. Some of the key players of the market are Intercept, Galmed Pharmaceuticals, Genfit, Allergan, Intercept and Gilead Sciences which are exclusively involved in the NASH market. Hence, the report covers the in depth analysis of NASH market along with current trends and comprehensive analysis of all the geographical regions. Also, the profile and growth of major key players are thoroughly analyzed in order to understand the competitive outlook of the global market.

Key Questions Answered

- Prevalent cases of NASH Disease in the US, EU5, and Japan; 2016-2024
- Sub-type specific prevalent cases of NASH Disease in the US, EU5, and Japan; 2016-2024
- Diagnosed cases of NASH Disease in the US, EU5, and Japan; 2016-2024
- Market size of NASH Disease in the US, EU5, and Japan; 2016-2024
- Therapy wise market size of NASH Disease in the US, EU5, and Japan; 2016-2024

- Product Profile of Current Therapies: Elafibranor, Cenicriviroc, Selonsertib, Obeticholic acid
- Drug analysis of NASH Disease
- Pipeline product analysis of NASH Disease
- Detailed analysis of growth drivers, and challenges
- Detailed Company Profiling of Key Market Players: Gilead, Intercept, Allergan, Galmed, and Genfit

About EffeMarket

EffeMarket provides market and business research solutions to clients in over 20 industries through syndicated studies, custom research, consulting engagements and newsletters. Our experienced analyst and widespread network of experts ensures accuracy within studies and provides our patrons with extensively researched, fact-based insights that help you to take better decisions.

Disclaimer

EffeMarket reports and their contents, including all the analysis and research containing valuable market information, are provided to a select group of customers in response to orders. Our customers acknowledge when ordering that EffeMarket reports including all research and insights in their entirety are for our customers' internal use and not for general publication or disclosure to third parties. The market information is based primarily on secondary research and interviews and therefore, is subject to changes. EffeMarket takes no responsibility for any incorrect information supplied to us through such sources.

Contact US

For any questions and updates, please contact:

Sales@effemarket.com

Support@effemarket.com

Website: www.effemarket.com

Phone:

US: +1-972-256-8133

UK: +44-203-286-8233

IN: +91 120 4561797

Address: Effectual Knowledge Services Pvt. Ltd. B-55, Sector 2, Noida – 201301, U.P., India

US Office – New York

Effectual Knowledge Services, Inc. 425 Broadhollow Road, Suite 427, Melville | NY 11747